Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis

20260 citationsJournal Article

Authors

Shugo Yajima · Tokyo Medical and Dental University

Soichiro Yoshida · Tokyo Medical and Dental University

Wei Chen · Tokyo Medical and Dental University

Hiroko Sato · Tokyo Medical and Dental University

Akihiro Hirakawa · Tokyo Medical and Dental University

Hiroshi Fukushima · Tokyo Medical and Dental University

Yuki Nakamura

Abstract

EV exhibited real-world efficacy in Japanese mUC patients comparable to the eligible patients' outcomes in the EV-301 trial. Ineligible patients showed statistically inferior outcomes.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Esophageal Cancer Research and Treatment Urinary and Genital Oncology Studies

Publication Details

Published in: Japanese Journal of Clinical Oncology

DOI: 10.1093/jjco/hyag012

Field-Weighted Citation Impact: 0.00

Command Palette

Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis

Authors

Abstract

Topics & Keywords

Publication Details